Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials
Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials
About this item
Full title
Author / Creator
Moro, Ruth N , Scott, Nigel A , Vernon, Andrew , Tepper, Naomi K , Goldberg, Stefan V , Schwartzman, Kevin , Leung, Chi-Chiu , Schluger, Neil W , Belknap, Robert W , Chaisson, Richard E , Narita, Masahiro , Machado, Elizabeth S , Lopez, Marta , Sanchez, Jorge , Villarino, Margarita E and Sterling, Timothy R
Publisher
United States: American Thoracic Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Thoracic Society
Subjects
More information
Scope and Contents
Contents
Data are limited regarding the safety of 12-dose once-weekly isoniazid (H, 900 mg) plus rifapentine (P, 900 mg) (3HP) for latent infection treatment during pregnancy.
To assess safety and pregnancy outcomes among pregnant women who were inadvertently exposed to study medications in two latent tuberculosis infection trials (PREVENT TB or iAdhere)...
Alternative Titles
Full title
Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6624829
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6624829
Other Identifiers
ISSN
2329-6933
E-ISSN
2325-6621
DOI
10.1513/AnnalsATS.201704-326OC
